Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...
The firm is testing the modified nucleotide drug ateganosine in a Phase II study with a PD-1 inhibitor in patients with non-small cell lung cancer.
In the meeting, the firm will discuss with the agency new, positive three-month data from the pediatric cohort of the Phase I/II OPGx-LCA5-1001 trial.
By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.
NEW YORK – AstraZeneca and Daiichi Sankyo on Monday said they will seek regulatory approval for the antibody-drug conjugate Enhertu (trastuzumab deruxtecan) in HER2-positive early breast cancer ...
NEW YORK – Taiho Oncology and Cullinan Therapeutics are advancing the next-generation EGFR inhibitor zipalertinib in two indications, for EGFR-mutant non-small cell lung cancer patients who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback